SI
ALXN

SII Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

SII Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,531
Closed -$214K – 618
2017
Q3 		$214K Buy
+1,531
New +$208K 0.01% 539
2016
Q4 		– Sell
-2,061
Closed -$255K – 631
2016
Q3 		$255K Buy
2,061
+8
+0.4% +$1.03K 0.02% 479
2016
Q2 		$241K Sell
2,053
-4,779
-70% -$678K 0.02% 492
2016
Q1 		$951K Buy
6,832
+145
+2% +$21.3K 0.09% 208
2015
Q4 		$1.27M Buy
6,687
+890
+15% +$155K 0.16% 120
2015
Q3 		$904K Buy
5,797
+454
+8% +$82.8K 0.1% 189
2015
Q2 		$963K Buy
5,343
+2,744
+106% +$474K 0.11% 176
2015
Q1 		$449K Buy
2,599
+189
+8% +$34.2K 0.05% 310
2014
Q4 		$445K Buy
2,410
+163
+7% +$30.2K 0.06% 275
2014
Q3 		$370K Buy
+2,247
New +$369K 0.05% 321

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SII Investments's ALXN Position: Q4 2017 in Review

SII Investments sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 1,531 shares — an estimated $214K sold.

SII Investments first reported a position in ALXN in Q3 2014 and held it in 10 quarters. The position peaked at $1.27M in Q4 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • SII Investments reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • SII Investments sold 1,531 Alexion Pharmaceuticals shares in Q4 2017, an estimated $214K.
  • SII Investments first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 10 quarters.
  • SII Investments's Alexion Pharmaceuticals position peaked at $1.27M in Q4 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on SII Investments's 13F filing for Q4 2017, filed 9 Feb 2018.